Takeda Pharmaceutical Company Limited - Depositary Receipt (Common Stock)
DE ˙ DB ˙ US8740602052
12,80 € ↓ -0,10 (-0,78%)
2026-06-04
AKTIENPREIS
SecurityDE:TKDA / Takeda Pharmaceutical Company Limited - Depositary Receipt (Common Stock)
InstitutionCerity Partners LLC
Latest Disclosed Ownership136,388 shares
Latest Disclosed Value $ 2,525,892
Cerity Partners LLC reports 12.11% increase in ownership of TKDA / Takeda Pharmaceutical Company Limited - Depositary Receipt (Common Stock)

On May 15, 2026 - Cerity Partners LLC filed a 13F-HR form disclosing ownership of 136,388 shares of Takeda Pharmaceutical Company Limited - Depositary Receipt (Common Stock) (DE:TKDA) valued at $2,154,930 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 11, 2026 disclosing 121,660 shares of Takeda Pharmaceutical Company Limited - Depositary Receipt (Common Stock). This represents a change in shares of 12.11% during the quarter. The current value of the position is $1,745,766 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 136,388 14,728 12.11 2,526 33.18 0.0018
2026-02-11 2025-12-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 121,660 -33,829 -21.76 1,897 -16.70 0.0028
2025-10-22 2025-09-30 13F TAKEDA PHARMACEUTICAL COM 874060205 155,489 -4,374 -2.74 2,276 -7.89 0.0037
2025-08-13 2025-06-30 13F TAKEDA PHARMACEUTICAL ADR 874060205 159,863 578 0.36 2,471 4.35 0.0044
2025-04-30 2025-03-31 13F TAKEDA PHARMACEUTICAL Stock 874060205 159,285 71,634 81.73 2,369 96.68 0.0048
2025-02-13 2024-12-31 13F TAKEDA PHARMACEUTICAL COM 874060205 87,651 -39,420 -31.02 1,204 -33.33 0.0026
2024-11-12 2024-09-30 13F TAKEDA PHARMACEUTICAL Stock 874060205 127,071 61,271 93.12 1,807 112.22 0.0040
2024-08-13 2024-06-30 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 65,800 -47,071 -41.70 851 -45.69 0.0022
2024-05-14 2024-03-31 13F TAKEDA PHARMACEUTICAL Equities 874060205 112,871 49,903 79.25 1,568 74.50 0.0041
2024-01-26 2023-12-31 13F TAKEDA PHARMACEUTICAL Equity 874060205 62,968 -4,556 -6.75 899 -13.98 0.0030
2023-11-14 2023-09-30 13F TAKEDA PHARMACEUTICAL Equities 874060205 67,524 7,301 12.12 1,045 10.48 0.0051
2023-08-14 2023-06-30 13F TAKEDA PHARMACEUTICAL Equities 874060205 60,223 -2,072 -3.33 946 -73.27 0.0037
2023-05-11 2023-03-31 13F TAKEDA PHARMACEUTICAL COM 874060205 62,295 7,304 13.28 3,535 312.49 0.0083
2023-02-15 2022-12-31 13F TAKEDA PHARMACEUTICAL COM 874060205 54,991 -22,936 -29.43 858 -15.23 0.0055
2022-11-14 2022-09-30 13F TAKEDA PHARMACEUTICAL COM 874060205 77,927 24,365 45.49 1,011 34.44 0.0122
2022-08-10 2022-06-30 13F TAKEDA PHARMACEUTICAL COM 874060205 53,562 21,366 66.36 752 63.83 0.0083
2022-04-25 2022-03-31 13F TAKEDA PHARMACEUTICAL COM 874060205 32,196 13,507 72.27 459 81.42 0.0071
2022-02-14 2021-12-31 13F TAKEDA PHARMACEUTICAL Stock 874060205 18,689 4,904 35.57 253 11.95 0.0039
2021-10-25 2021-09-30 13F Takeda Pharma Co F Sponsored ADR Stock 874060205 13,785 -34 -0.25 226 -3.00 0.0050
2021-08-11 2021-06-30 13F TAKEDA PHARMACEUTICAL Stock 874060205 13,819 -882 -6.00 233 -13.06 0.0051
2021-08-11 2021-03-31 13F/A-1 TAKEDA PHARMACEUTICAL Stock 874060205 14,701 -13,978 -48.74 268 -48.66 0.0064
2021-05-12 2021-03-31 13F TAKEDA PHARMACEUTICAL Stock 874060205 24,363 -4,316 445 0.0132
2021-02-11 2020-12-31 13F TAKEDA PHARMACEUTICAL Stock 874060205 28,679 725 2.59 522 4.61 0.0167
2020-11-12 2020-09-30 13F TAKEDA PHARMACEUTICAL COM 874060205 27,954 0 0.00 499 -0.40 0.0205
2020-08-17 2020-06-30 13F/A-1 TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 27,954 9,346 50.23 501 77.66 0.0277
2020-08-14 2020-06-30 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 27,954 9,346 501 27,631.3482
2020-05-14 2020-03-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 18,608 546 3.02 282 -20.79 0.0178
2020-02-14 2019-12-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 18,062 884 5.15 356 20.68 0.0181
2019-10-30 2019-09-30 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 17,178 -3,659 -17.56 295 -20.05 0.0173
2019-08-14 2019-06-30 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 20,837 -4,929 -19.13 369 -29.71 0.0233
2019-05-14 2019-03-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 25,766 25,766 525 0.0353
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.